AG
AUTL

Aperio Group’s Autolus Therapeutics AUTL Stock Holding History

Aperio Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$111K Buy
12,419
+1,047
+9% +$11.2K ﹤0.01% 2373
2020
Q3 		$132K Buy
+11,372
New +$165K ﹤0.01% 2291
2020
Q2 		– Sell
-18,317
Closed -$110K – 2341
2020
Q1 		$110K Buy
18,317
+8,131
+80% +$75.2K ﹤0.01% 2208
2019
Q4 		$134K Buy
+10,186
New +$133K ﹤0.01% 2247

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aperio Group's AUTL Position: Q4 2020 in Review

Aperio Group increased its Autolus Therapeutics (AUTL) stake by 9.2% in Q4 2020, buying an estimated $11.2K and bringing the position to 12,419 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Aperio Group first reported a position in AUTL in Q4 2019 and has held it in 4 quarters since. The position peaked at $134K in Q4 2019. 48 funds tracked by Wall St. Rank hold AUTL as of Q4 2020.

  • Aperio Group held 12,419 shares of Autolus Therapeutics worth $111K as of Q4 2020.
  • Aperio Group bought 1,047 Autolus Therapeutics shares in Q4 2020, an estimated $11.2K.
  • Autolus Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2373 holding.
  • Aperio Group first reported a position in Autolus Therapeutics in Q4 2019 and has held it in 4 quarters since.
  • Aperio Group's Autolus Therapeutics position peaked at $134K in Q4 2019.
  • 48 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.